Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…, ANI was administered concomitantly with antimalarials (n=16), mycophenolate mofetil (n=11), tacrolimus (n=4), azathioprine (n=2), methotrexate (n=1…
…omitant immunosuppressive biologics in LN patients treated with voclosporin. This is notable given the unique and possibly synergistic effe…
…ected. Forty-eight patients received B-cell targeted therapies (belimumab 40=; rituximab n=8). For these, treatment duration, reasons for…
…3), organ damage (SLICC/ACR Damage Index) (SDI), treatments and prednisone dosages for every visit were collected.We compared patients nev…
…b in 25, belimumab in 16, obinutuzumab in 2, voclosporin in 21, tacrolimus in 6, cyclosporin-A in 4 and azathioprine in 3 patients. Six pa…
…A 1:1280, anti-dsDNA positive, low C3/C4). Initial therapy with hydroxychloroquine (200 mg/day) and low-dose prednisone (7.5 mg/day) achieved clin…
…h results from pivotal trials (TULIP-1 and TULIP-2), supporting anifrolumab as an effective therapeutic option for patients with SLE, altho…
…frolumab treatmentConclusions In this real-world Danish cohort, anifrolumab produced substantial and sustained reductions in disease activi…
…sant; 3/5 rituximab and 4/5 belimumab. Concomitant therapy: 5/5 hydroxychloroquine, 4/5 MMF/Na, 5/5 prednisone (mean baseline dose 15 mg/day (10-1…
…Objectives Belimumab (BEL) is a B-cell modulator targeting the central immunopathoge…
…Objectives Belimumab (BEL) is a B-cell modulating anti-BLyS mAb approved for SLE (20…
…s received BLM after bDMARD. The main bDMARD use before BLM was rituximab in the 85.3% of patients. Baseline characteristics are summariz…